Office of Professional Education

Two free CME/CNE/CPE live webinars

Virus-neutralizing monoclonal antibodies (NAbs) have the potential to change the care of COVID-19 from a reactive approach for people with severe disease to a proactive approach that prevents those with milder or more moderate disease from progressing. This change in the COVID-19 treatment paradigm places clinicians in outpatient settings on the front lines of care for those at high risk of COVID-19 progression to severe disease. 

Join us for a 2-session educational experience designed to help healthcare providers recognize patients with mild to moderate COVID-19 at high risk of progression, counsel and educate patients and other care providers on those risks and the available treatment options, and orient patients to infusion centers.

Session Dates and Times:


Session 1: Evidence and the Evolving Treatment Landscape for COVID-19 with Virus Neutralizing Antibodies

  • Thursday, May 13, 2021 – 10:00 am to 11:00 am MT 
    (Begins at 12:00 pm ET, 11:00 am CT, and 9:00 am PT)

    ► Register here for the May 13th webinar.


Session 2: Enhancing Access to COVID-19 Breakthrough Therapy with Virus Neutralizing Antibodies: Strategies for Equitable Care

  • Friday, May 21, 2021 – 3:00 pm to 4:00 pm MT 
    (Begins at 5:00 pm ET, 4:00 pm CT, and 2:00 pm PT)

    ►Register here for the May 21st webinar.


Target Audience:

The primary intended audience for this education includes practicing US HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, registered nurses, and pharmacists.


Learning Objectives:

Upon completion of these activities, the participant will be better able to:

  1. Understand the rationale for and process by which the FDA issues an EUA for agents developed for the treatment of COVID-19
  2. Recognize SARS-CoV-2-infected patients with mild to moderate COVID-19 who could benefit from NAbs treatments 
  3. NAbsCounsel and orient SARS-CoV-2-infected patients displaying mild to moderate symptoms to appropriate treatment or care based on their risk for hospitalization


Program Faculty:

Rebecca C. Keith, MD
Associate Professor
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
Interstitial Lung Disease Program
Autoimmune Lung Center
National Jewish Health, Denver, CO
Jared J. Eddy, MD, MPhil, MSc
Assistant Professor
Director of Infection Prevention & Antimicrobial Stewardship
Division of Mycobacterial & Respiratory Infections
Department of Medicine
National Jewish Health, Denver, CO



For questions, please email the Office of Professional Education at National Jewish Health or call 303.398.1000 or 800.844.2305. 

Accreditation and Designation Statements:

Physicians:  National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates each live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses: Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours for each activity.

Pharmacists: National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

National Jewish Health designates each live activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 

Session 1: Universal Activity Number: 0831-0000-21-014-L01-P. Activity Type: Knowledge-based.
Session 2: Universal Activity Number: 0831-0000-21-015-L01-P. Activity Type: Knowledge-based.

To earn credit, attendees must participate in the live activity, pass the post-test with a minimum score of 70%, and complete the activity evaluation. 


This educational activity is supported by an educational grant from Eli Lilly.